CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Vectibix for mCRC – Details

Project Number PC0060-000
Brand Name Vectibix
Generic Name Panitumumab
Strength 20mg/mL (100mg vial)
Tumour Type Gastrointestinal
Indication Metastatic Colorectal Cancer
Funding Request For the treatment of patients with WT RAS mCRC in first line treatment setting in combination with FOLFOX
Review Status Complete
Pre Noc Submission Yes
NOC Date August 31, 2015
Manufacturer Amgen Canada Inc.
Sponsor Amgen Canada Inc.
Submission Date April 15, 2015
Submission Deemed Complete April 22, 2015
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ April 29, 2015
Check-point meeting July 6, 2015
pERC Meeting September 17, 2015
Initial Recommendation Issued October 1, 2015
Feedback Deadline ‡ October 16, 2015
pERC Reconsideration Meeting November 19, 2015
Final Recommendation Issued December 3, 2015
Notification to Implement Issued December 18, 2015
Therapeutic Area Metastatic Colorectal Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.